0.33 USD
▲+0.01+5.16%
盘后 0.31 -1.99%
2026-08-03
市值
$1.06M
市盈率
—
EPS
-8.00
股息率
—
52 周区间
0.25 – 5.60
成交量
635.88K
Beta
1.88
目标价
—
52W 低 0.2552W 高 5.60
价格走势
公司简介
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in Apr...